Apria, Inc. APR 深 滬
已收盤 03-29 16:00:00 美东时间
37.50
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 37.50
- 總市值 13.40亿
- 52周最高 40.00
- 市盈率 靜 20.53
- 換手率 0.00%
- 52周最低 25.01
- 委 比 0.00%
- 總股本 3574.13万
- 歷史最高 40.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 20.07
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aprea To Feature Preliminary Results From ACESOT-1051 Trial Through September 17 In Poster Presentation At AACR-NCI-EORTC
3 out of 4 patients achieved stable disease (per RECIST v1.1) at the 100 mg APR-1051 dose level in heavily pretreated gastrointestinal and gynecologic malignanciesDisease stabilization observed in patients with tumors
10-24 20:35
Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051
<p>Aprea Therapeutics reported early results from its Phase 1 ACESOT-1051 trial, showing that 75% of heavily pretreated gastrointestinal and gynecologic cancer patients achieved stable disease at the 100 mg dose of APR-1051, its WEE1 kinase inhibitor. Disease stabilization was observed in tumors with mutations relevant to WEE1 inhibition, including FBXW7, CCNE1, KRAS G12V, and TP53. Dose escalation continues, with patients now enrolling in the 15...
10-24 12:30
Flexible Payments Come To All Wayfair Stores Thanks To Affirm
Affirm expands partnership with Wayfair, integrating pay-over-time solution at checkout. Move simplifies payments for shoppers.
10-21 23:48
The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners
DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development...
10-21 20:05
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
Aprea Therapeutics identified the recommended Phase 2 dose of 1,100 mg once daily for ATRN-119, an oral ATR inhibitor, in the monotherapy arm of its ABOYA-119 Phase 1/2a study for patients with advanced solid tumors. The company is pausing further enrollment in monotherapy arms to focus on strategic high-value combinations, such as DNA-damaging agents and immune checkpoint inhibitors, based on preclinical data suggesting synergistic anti-tumor ef...
10-15 12:00
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
Aprea Therapeutics announced that two abstracts for its clinical programs, APR-1051 and ATRN-119, have been accepted for poster presentations at the EORTC-NCI-AACR conference in Boston. Both presentations will occur on October 24th during Poster Session B in Exhibit Hall D. APR-1051 is a WEE1 inhibitor targeting cancer-associated gene alterations, while ATRN-119 is an ATR inhibitor for advanced solid tumors with DNA damage. The posters will be av...
10-14 12:00
Block’s Cash App post-purchase BNPL is gaining steam, could lift EPS growth: UBS
Block’s (NYSE:XYZ) newest lending feature inside Cash App, the ability to convert recent Cash App Card purchases into installment plans, has scaled quickly since launching in February and could become...
10-13 03:17
Apyx Medical’s Renuvion APR System: Promising Results in Facelift Surgery Study
Apyx Medical (($APYX)) announced an update on their ongoing clinical study. Stu...
10-07 00:30
VC范式焦虑：从资产创造到交易导向，下一步是什么？
Tether 决定出手拯救加密 VC 行业。 9.24 日，由美国商务部长卢特尼克家族撮合，USDT 发行方 Tether 有意以 5000 亿估值出让 3%...
09-25 16:00
君乐宝X艾利丹尼森：乳品包装也要实现高质量"瓶到瓶"回收
上海2025年9月25日 /美通社/ -- 在超市冷柜前驻足的那一刻，消费者的目光总是先被透明瓶中"新鲜可见"的乳制品所吸引。PET瓶，正悄然改变着乳制品的视觉...
09-25 15:07
